|
|
Have Questions?
Global Headquarters
Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157
North America
Tel: 1-617-573-9450
Fax: 1-617-573-9542
Japan
Tel: +81 (0)80-1164-4754
Request a Demo
What our customers are saying
When I think of the future, I think of EvaluatePharma
Senior Director,
Global pharmaceutical company
EvaluateMedTech World Preview 2017, Outlook to 2022
Worldwide Medtech Sales Forecast to Reach $522 Billion by 2022 with a CAGR of 5.1% between 2016 and 2022
|
The new edition of EvaluateMedTech World Preview 2017, Outlook to 2022 shows Medtronic was the leading medtech company in 2016 with sales of almost $30bn. They will retain the crown in 2022 with sales forecast to reach $37.7bn.
Our annual report highlights trends in medtech including: consensus sales forecasts of leading industry analysts by device area to 2022; the top 20 companies in 2022; R&D spend current and future; FDA approvals; M&A; venture financing; IPOs; and enterprise value.
Key Highlights
- Total value of medtech M&A deals rises by a massive 178% in H1 2017
- In vitro diagnostics is expected to remain the largest medtech segment in 2022 with annual sales of $70bn; Roche remains top player with expected sales of $12.8bn in 2022
- Venture capital investment looks to be on track to at least match 2016’s total
- Total value of medtech venture financing deals rises 56% in H1 2017 despite the number of deals falling by 11%
This analysis is based on in-depth consensus forecast models for the top 300 global medtech companies available within the EvaluateMedTech service.
|
Confirm your details on form below to download this report
|